Not Yet RecruitingNot Applicable

Evaluation of Remnant Cholesterol Levels and Monocyte-to-HDL-cholesterol Ratio as Predictors of Coronary Artery Disease Severity in Patients With Acute Coronary Syndrome

54 participantsStarted 2025-02-08

Plain-language summary

1. Evaluation of serum level of remnant cholesterol and monocyte/HDL ratio as predictors of severity of coronary artery disease in patients with acute coronary syndrome. 2. Evaluate predictive value of remnant cholesterol serum level and monocyte/HDL ratio to detect in-hospital worse clinical outcomes and 45 days major adverse cardiac events (MACE) after acute coronary syndrome.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with acute coronary syndrome presented to ER of Assiut university hospital scheduled for primary PCI and able to provide informed consent. Exclusion Criteria: * Patients on previous statin therapy. * Patients with severe renal dysfunction (creatinine clearance \<30 mL/min) or other contraindications to PCI. * Patients with missed data or who couldn't be followed up

What they're measuring

Evaluation of serum level of remnant cholesterol and monocyte/HDL ratio as predictors of severity of coronary artery disease in patients with acute coronary syndrome.

Timeframe: Baseline

Trial details

NCT IDNCT06757777

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-02-08

Contact for this trial

Isaac A Ghaly, Resident

+201201979010 ishaq.16287235@med.aun.edu.eg

View on ClinicalTrials.gov More Acute Coronary Syndrome trials